Actavis plc, of Dublin, confirmed that the U.S. District Court for the District of New Jersey found that U.S. Patent Nos. 7,645,459 and 7,645,460 protecting bisphosphonate Atelvia (risedronate sodium delayed-release tablets, 35 mg) in the U.S. are invalid.